Zentalis Pharmaceuticals Inc

Open

4.46 2.53

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.43

Max

4.55

Schlüsselkennzahlen

By Trading Economics

Einkommen

-136K

-35M

EPS

-0.503

Angestellte

106

EBITDA

2.2M

-35M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+56.95% upside

Dividenden

By Acuity

Nächstes Ergebnis

4. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

33M

328M

Vorheriger Eröffnungskurs

1.93

Vorheriger Schlusskurs

4.46

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Juli 2026, 23:52 UTC

U.S. job growth disappoints, reducing Fed rate hike expectations, while global equities rise amid easing U.S.-Iran tensions and stable oil prices.

3. Juli 2026, 23:52 UTC

European equity indices rise as weaker U.S. job growth dampens Fed rate hike expectations, while ECB signals caution amid mixed economic indicators.

3. Juli 2026, 23:52 UTC

Global equity markets rise as U.S. job growth disappoints and European economic indicators show mixed signals, prompting cautious outlook on interest rate hikes.

3. Juli 2026, 23:52 UTC

Asia equity markets rise as U.S. jobs data eases Fed rate hike concerns, boosting sentiment and commodities like gold and oil.

3. Juli 2026, 23:52 UTC

Brazil's Inflation Rate Release on July 10, 2026: Market Awaits Insights Amid World Cup Spending Boost and Economic Uncertainty.

3. Juli 2026, 23:52 UTC

Brazil's Inflation Rate Release on July 10, 2026: Market Eyes Potential Shifts Amid Service Sector Growth and Global Pressures.

3. Juli 2026, 23:41 UTC

Spain's Consumer Confidence Index Holds Steady at 77.7 Amid Geopolitical Tensions and Inflation Concerns

3. Juli 2026, 23:41 UTC

Correlated Moves
Macro News

Bitcoin is gaining ground amid improved sentiment following a weaker U.S. jobs report, which has eased expectations for Federal Reserve interest rate hikes.

3. Juli 2026, 23:31 UTC

Mexico's June 2026 Inflation Rate Release on July 9 Expected Amid Cautious Optimism Over Global Price Trends.

3. Juli 2026, 23:31 UTC

Mexico's Inflation Rate MoM Release on July 9, 2026: Market Anticipates Impact from U.S. Monetary Policy Adjustments and Global Economic Pressures.

3. Juli 2026, 23:22 UTC

U.S. Balance of Trade Report Set for July 7, Anticipating $78.8 Billion Deficit Amid Labor Market Concerns and Global Economic Volatility

3. Juli 2026, 23:22 UTC

U.S. Imports Data Release on July 7, 2026: Analysts Anticipate Cautious Optimism Amid Tariff Influences and Supply Chain Concerns

3. Juli 2026, 23:22 UTC

U.S. Exports Data Release on July 7, 2026, Expected to Show Continued Growth Amid Geopolitical Tensions and Trade Policy Changes

3. Juli 2026, 23:22 UTC

Canada's Trade Balance Expected to Show C$2.4 Billion Surplus Amid Optimism in Export Performance and Market Uncertainty Over U.S. Trade Relations

3. Juli 2026, 23:21 UTC

Correlated Moves

The Russell 2000 Index is trading lower in after-market hours, reflecting a broader market decline linked to disappointing U.S. job growth data.

3. Juli 2026, 23:21 UTC

Correlated Moves

The S&P 500 Index is trading lower in after-market hours, reflecting minimal movement since Friday's close amid weaker U.S. jobs data.

3. Juli 2026, 23:21 UTC

Nasdaq 100 Index declines slightly in after-market trading, remaining flat overall. Recent U.S. nonfarm payrolls report eases interest rate hike concerns.

3. Juli 2026, 23:21 UTC

Correlated Moves

The Dow Jones Index is trading lower in after-market hours, reflecting a weak performance since Friday's close amid disappointing U.S. nonfarm payrolls data.

3. Juli 2026, 23:21 UTC

The FTSE 100 Index is trading lower in after-market hours, with no specific news identified to explain the decline.

3. Juli 2026, 23:11 UTC

Brazil's Retail Sales MoM report on July 8, 2026, signals cautious market sentiment amid recent declines and economic uncertainty.

3. Juli 2026, 23:11 UTC

Correlated Moves

XRP is trading higher, buoyed by positive sentiment in the digital currency market and softer U.S. nonfarm payrolls data impacting interest rate expectations.

3. Juli 2026, 23:11 UTC

Correlated Moves
Macro News

Ethereum is trading higher since Thursday, supported by increased interest in Pepeto and a correlated rise in Bitcoin. Earlier, it pulled back from a session high.

3. Juli 2026, 23:01 UTC

Declining 30-Year Mortgage Rates Signal Potential Boost in U.S. Housing Market Confidence and Activity

3. Juli 2026, 23:01 UTC

Terra is trading higher during Friday's session, maintaining upward momentum since Thursday. No specific news has been identified to explain this price movement.

3. Juli 2026, 23:01 UTC

Cardano is trading higher today, continuing a notable increase since Thursday's close. The asset remains above its 20-day moving average.

3. Juli 2026, 22:51 UTC

Brazil's Central Bank to Release Key Interest Rate Insights Amid Global Economic Influences on July 6, 2026.

3. Juli 2026, 22:51 UTC

Japan's Current Account data release on July 7, 2026, forecasts a JPY 4.1 trillion surplus amid cautious market sentiment and potential currency volatility concerns.

3. Juli 2026, 22:51 UTC

The DAX 30 Index is trading lower in after-market hours, with no specific news identified. Recent U.S. jobs data may be influencing market sentiment.

3. Juli 2026, 22:31 UTC

UK Housing Market Faces Negative Outlook as RICS House Price Balance Forecasts -0.32% Amid Economic Pressures and Inflation Concerns

3. Juli 2026, 22:11 UTC

Japan's Household Spending Data Set for Release Amidst Declining Consumer Confidence and Currency Market Volatility

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

56.95% Vorteil

12-Monats-Prognose

Durchschnitt 7 USD  56.95%

Hoch 10 USD

Tief 4 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

4

Buy

3

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat